Revelation Biosciences
NASDAQ: REVBSan Diego, US · Founded 2020 · Delaware corporation
RevBio Sciences develops Gemini, an intravenously administered formulation of phosphorylated hexaacyl disaccharide (PHAD) designed to reduce inflammation-related damage by reprogramming the innate immune system to respond to stress such as trauma and infection in an attenuated way. The company works in therapeutics and immunology.
Founders & leadership
Revelation Biosciences was founded in 2020 by James M. Rolke.
Board
CL
Curt LaBelleBoard director
GF
George F. TidmarshBoard director
JC
Jennifer CarverBoard director
Funding
SEC filings, press & company announcements$10.5M disclosed across 3 of 7 rounds · 2020–2026
▶$5.1MraisedMay 2021 · 44 investors · BiotechnologyRule 506(b)
▶$5.1MraisedMay 2021 · 44 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Chester S. Zygmont IIIExecutive Officer
- Jennifer CarverDirector
- Jess RoperDirector
- James M. RolkeExecutive Officer, Director
- Curt LaBelleDirector
- George F. TidmarshDirector
- Offering amount
- $5.1M
- Amount sold
- $5.1M
- Minimum investment
- $5K
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$4.4MraisedApr 2021 · 61 investors · BiotechnologyRule 506(b)
▶$4.4MraisedApr 2021 · 61 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jess RoperDirector
- Chester S. Zygmont IIIExecutive Officer
- Curt LaBelleDirector
- George F. TidmarshDirector
- Jennifer CarverDirector
- James M. RolkeExecutive Officer, Director
- Offering amount
- $4.4M
- Amount sold
- $4.4M
- Minimum investment
- $13K
- Sales commissions
- $391.8K
- Placement agents
- National Securities Corporation
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$1MraisedJul 2020 · 10 investors · BiotechnologyRule 506(b)
▶$1MraisedJul 2020 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- George F. TidmarshDirector
- Chester S. ZygmontExecutive Officer, Director
- James M. RolkeDirector
- Offering amount
- $1M
- Amount sold
- $1M
- First sale
- May 2020
- Incorporated
- Limited Liability Company, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Seeking Alpha14 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Simply Wall St13 shared keywordsSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
TipRanks13 shared keywordsFinancial analysis and stock research platform.
Companies competing with Revelation Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Revelation Biosciences do?
- RevBio Sciences develops Gemini, an intravenously administered formulation of phosphorylated hexaacyl disaccharide (PHAD) designed to reduce inflammation-related damage by reprogramming the innate immune system to respond to stress such as trauma and infection in an attenuated way. The company works in therapeutics and immunology.
- Who founded Revelation Biosciences?
- Revelation Biosciences was founded by James M. Rolke in 2020.
- How much funding has Revelation Biosciences raised?
- Revelation Biosciences has disclosed $10.5M raised across 3 of its 7 known rounds.
- Where is Revelation Biosciences headquartered?
- Revelation Biosciences is headquartered in San Diego, US.